A combined analysis of 48 type 2 diabetes genetic risk variants shows no discriminative value to predict time to first prescription of a glucose lowering drug in danish patients with screen detected type 2 diabetes

PLoS ONE

Volumn 9, Issue 8, 2014, Pages

  Hornbak, Malene ^a,b   Allin, Kristine Højgaard ^a   Jensen, Majken Linnemann ^b,c   Lau, Cathrine Juel ^d   Witte, Daniel ^e   Jørgensen, Marit Eika ^c   Sandbæk, Annelli ^f   Lauritzen, Torsten ^f   Andersson, Åsa ^b   Pedersen, Oluf ^a,b,g   Hansen, Torben ^a,h  

^a Capital Region   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c STENO DIABETES CENTER   (Denmark)

^d GLOSTRUP UNIVERSITY HOSPITAL   (Denmark)

^e Luxembourg Clinical Proteomics Center (LCP) Luxembourg Institute of Health (LIH)   (Luxembourg)

^f AARHUS UNIVERSITY   (Denmark)

^g AARHUS UNIVERSITY   (Denmark)

^h UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA GLUCOSIDASE INHIBITOR; ANTIDIABETIC AGENT; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLITAZONE DERIVATIVE; GLUCAGON LIKE PEPTIDE 1 DERIVATIVE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN; INSULIN; METFORMIN; SULFONYLUREA DERIVATIVE; TRIACYLGLYCEROL;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BODY MASS; CONTROLLED STUDY; DANISH CITIZEN; DENMARK; DIABETOGENESIS; DISEASE COURSE; FEMALE; GENERAL PRACTITIONER; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; HEMOGLOBIN BLOOD LEVEL; HUMAN; INSULIN SENSITIVITY; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET BETA CELL; PANCREAS ISLET CELL FUNCTION; PRESCRIPTION; SINGLE NUCLEOTIDE POLYMORPHISM; TIME TO TREATMENT; TRIACYLGLYCEROL BLOOD LEVEL; DIABETES MELLITUS, TYPE 2; GENETIC PREDISPOSITION; GENETICS; INSULIN RESISTANCE; METABOLISM; MIDDLE AGED; PATHOLOGY; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR;

AGED; DENMARK; DIABETES MELLITUS, TYPE 2; DISEASE PROGRESSION; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; INSULIN-SECRETING CELLS; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK FACTORS;

EID: 84920993891     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0104837     Document Type: Article

References (54)

1. American Diabetes Association. (2006) Standards of medical care in diabetes - 2006. Diabetes Care 29 Suppl 1: S4-42.
2. Ali MK, McKeever BK, Imperatore G, Barker L, Gregg EW. (2012) Characteristics associated with poor glycemic control among adults with self-reported diagnosed diabetes - National Health and Nutrition Examination Survey, United States, 2007-2010. MMWR Morb Mortal Wkly Rep 61 Suppl: 32-37.
3. Hayward RA, Manning WG, Kaplan SH, Wagner EH, Greenfield S. (1997) Starting insulin therapy in patients with type 2 diabetes: effectiveness, complications, and resource utilization. JAMA 278: 1663-1669. (Pubitemid 27509513)
4. Hoerger TJ, Segel JE, Gregg EW, Saaddine JB. (2008) Is glycemic control improving in U.S. adults? Diabetes Care 31: 81-86.
5. Kristensen JK, Bak JF, Wittrup I, Lauritzen T. (2007) Diabetes prevalence and quality of diabetes care among Lebanese or Turkish immigrants compared to a native Danish population. Prim Care Diabetes 1: 159-165.
6. Rodbard HW, Jellinger PS, Davidson JA, Einhorn D, Garber AJ, et al. (2009) Statement by an American Association of Clinical Endocrinologists/ American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control. Endocr Pract 15: 540-559.
7. Cohen A, Horton ES. (2007) Progress in the treatment of type 2 diabetes: new pharmacologic approaches to improve glycemic control. Curr Med Res Opin 23: 905-917. (Pubitemid 46631494)
8. Cook MN, Girman CJ, Stein PP, Alexander CM, Holman RR. (2005) Glycemic control continues to deteriorate after sulfonylureas are added to metformin among patients with type 2 diabetes. Diabetes Care 28: 995-1000. (Pubitemid 40616602)
9. Fonseca VA. (2009) Defining and characterizing the progression of type 2 diabetes. Diabetes Care 32 Suppl 2: S151-S156.
10. United Kingdom Prospective Diabetes Study 24. (1998) A 6-year, randomized, controlled trial comparing sulfonylurea, insulin, and metformin therapy in patients with newly diagnosed type 2 diabetes that could not be controlled with diet therapy. United Kingdom Prospective Diabetes Study Group. Ann Intern Med 128: 165-175.
11. Wilson PW, Meigs JB, Sullivan L, Fox CS, Nathan DM, et al. (2007) Prediction of incident diabetes mellitus in middle-aged adults: the Framingham Offspring Study. Arch Intern Med 167: 1068-1074. (Pubitemid 46835795)
12. Lyssenko V, Almgren P, Anevski D, Perfekt R, Lahti K, et al. (2005) Predictors of and longitudinal changes in insulin sensitivity and secretion preceding onset of type 2 diabetes. Diabetes 54: 166-174. (Pubitemid 40105109)
13. Voight BF, Scott LJ, Steinthorsdottir V, Morris AP, Dina C, et al. (2010) Twelve type 2 diabetes susceptibility loci identified through large-scale association analysis. Nat Genet 42: 579-589.
14. Dupuis J, Langenberg C, Prokopenko I, Saxena R, Soranzo N, et al. (2010) New genetic loci implicated in fasting glucose homeostasis and their impact on type 2 diabetes risk. Nat Genet 42: 105-116.
15. Morris AP, Voight BF, Teslovich TM, Ferreira T, Segre AV, et al. (2012) Large-scale association analysis provides insights into the genetic architecture and pathophysiology of type 2 diabetes. Nat Genet 44: 981-990.
16. Hivert MF, Jablonski KA, Perreault L, Saxena R, McAteer JB, et al. (2011) Updated genetic score based on 34 confirmed type 2 diabetes Loci is associated with diabetes incidence and regression to normoglycemia in the diabetes prevention program. Diabetes 60: 1340-1348.
17. Lyssenko V, Jonsson A, Almgren P, Pulizzi N, Isomaa B, et al. (2008) Clinical risk factors, DNA variants, and the development of type 2 diabetes. N Engl J Med 359: 2220-2232.
18. Meigs JB, Shrader P, Sullivan LM, McAteer JB, Fox CS, et al. (2008) Genotype score in addition to common risk factors for prediction of type 2 diabetes. N Engl J Med 359: 2208-2219.
19. Lauritzen T, Griffin S, Borch-Johnsen K, Wareham NJ, Wolffenbuttel BH, et al. (2000) The ADDITION study: proposed trial of the cost-effectiveness of an intensive multifactorial intervention on morbidity and mortality among people with Type 2 diabetes detected by screening. Int J Obes Relat Metab Disord 24 Suppl 3: S6-11.
20. Glumer C, Carstensen B, Sandbaek A, Lauritzen T, Jorgensen T, et al. (2004) A Danish diabetes risk score for targeted screening: the Inter99 study. Diabetes Care 27: 727-733. (Pubitemid 38280541)
21. Lauritzen T, Sandbaek A, Carlsen AH, Borch-Johnsen K. (2012) All-cause mortality and pharmacological treatment intensity following a high risk screening program for diabetes. A 6.6 year follow-up of the ADDITION study, Denmark. Prim Care Diabetes 6: 193-200.
22. Christensen JO, Sandbaek A, Lauritzen T, Borch-Johnsen K. (2004) Population-based stepwise screening for unrecognised Type 2 diabetes is ineffective in general practice despite reliable algorithms. Diabetologia 47: 1566-1573. (Pubitemid 39371639)
23. Alberti KG, Zimmet PZ. (1998) Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 15: 539-553. (Pubitemid 28319935)
24. Type 2 Diabetes in General Practice - Diagnosis and Treatment. Guideline from the Danish College of General Practitioners. 1999. 1-10-2014.
25. Prevention of Ischemic Heart Disease in General Practice. Guideline from the Danish College of General Practitioners. 1998.
26. Sandbaek A, Lauritzen T, Borch-Johnsen K, Mai K, Christiansen JS. (2005) The comparison of venous plasma glucose and whole blood capillary glucose in diagnoses of Type 2 diabetes: a population-based screening study. Diabet Med 22: 1173-1177. (Pubitemid 41224176)
27. Friedewald WT, Levy RI, Fredrickson DS. (1972) Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 18: 499-502.
28. Kildemoes HW, Sorensen HT, Hallas J. (2011) The Danish National Prescription Registry. Scand J Public Health 39: 38-41.
29. WHO Collaborating Centre for Drug Statistics Methodology. International language for drug utilization research. 23-1-2014.
30. Iwata M, Maeda S, Kamura Y, Takano A, Kato H, et al. (2012) Genetic risk score constructed using 14 susceptibility alleles for type 2 diabetes is associated with the early onset of diabetes and may predict the future requirement of insulin injections among Japanese individuals. Diabetes Care 35: 1763-1770.
31. Cornelis MC, Qi L, Zhang C, Kraft P, Manson J, et al. (2009) Joint effects of common genetic variants on the risk for type 2 diabetes in U.S. men and women of European ancestry. Ann Intern Med 150: 541-550.
32. Andersson EA, Allin KH, Sandholt CH, Borglykke A, Lau CJ, et al. (2013) Genetic risk score of 46 type 2 diabetes risk variants associates with changes in plasma glucose and estimates of pancreatic beta-cell function over 5 years of follow-up. Diabetes 62: 3610-3617.
33. Zhou AK, Donnelly LA, Morris AD, Franks PW, Jennison C, et al. (2013) Clinical and genetic determinants of progression of type 2 diabetes: A DIRECT Study. Diabetes Care.
34. Ringborg A, Lindgren P, Yin DD, Martinell M, Stalhammar J. (2010) Time to insulin treatment and factors associated with insulin prescription in Swedish patients with type 2 diabetes. Diabetes Metab 36: 198-203.
35. Pani LN, Nathan DM, Grant RW. (2008) Clinical predictors of disease progression and medication initiation in untreated patients with type 2 diabetes and A1C less than 7%. Diabetes Care 31: 386-390.
36. Che R, Motsinger-Reif AA. (2013) Evaluation of genetic risk score models in the presence of interaction and linkage disequilibrium. Front Genet 4: 138.
37. Iwata M, Maeda S, Kamura Y, Takano A, Kato H, et al. (2012) Genetic risk score constructed using 14 susceptibility alleles for type 2 diabetes is associated with the early onset of diabetes and may predict the future requirement of insulin injections among Japanese individuals. Diabetes Care 35: 1763-1770.
38. Kahn SE, Suvag S, Wright LA, Utzschneider KM. (2012) Interactions between genetic background, insulin resistance and beta-cell function. Diabetes Obes Metab 14 Suppl 3: 46-56.
39. Rosengren AH, Braun M, Mahdi T, Andersson SA, Travers ME, et al. (2012) Reduced insulin exocytosis in human pancreatic beta-cells with gene variants linked to type 2 diabetes. Diabetes 61: 1726-1733.
40. Cnop M, Vidal J, Hull RL, Utzschneider KM, Carr DB, et al. (2007) Progressive loss of beta-cell function leads to worsening glucose tolerance in first-degree relatives of subjects with type 2 diabetes. Diabetes Care 30: 677-682. (Pubitemid 46354352)
41. Levy J, Atkinson AB, Bell PM, McCance DR, Hadden DR. (1998) Beta-cell deterioration determines the onset and rate of progression of secondary dietary failure in type 2 diabetes mellitus: the 10-year follow-up of the Belfast Diet Study. Diabet Med 15: 290-296. (Pubitemid 28168508)
42. LeRoith D. (2002) Beta-cell dysfunction and insulin resistance in type 2 diabetes: role of metabolic and genetic abnormalities. Am J Med 113 Suppl 6A: 3S-11S.
43. U.K. prospective diabetes study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. U.K. Prospective Diabetes Study Group. (1995) Diabetes 44: 1249-1258.
44. Meneilly GS, Elliott T, Tessier D, Hards L, Tildesley H. (1996) NIDDM in the elderly. Diabetes Care 19: 1320-1325. (Pubitemid 26418608)
45. Gong Z, Muzumdar RH. (2012) Pancreatic function, type 2 diabetes, and metabolism in aging. Int J Endocrinol 2012: 320482.
46. Scheen AJ. (2005) Diabetes mellitus in the elderly: insulin resistance and/or impaired insulin secretion? Diabetes Metab 31 Spec No 2: 5S27-5S34.
47. Watson RT, Pessin JE. (2001) Intracellular organization of insulin signaling and GLUT4 translocation. Recent Prog Horm Res 56: 175-193.
48. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. (1998) Lancet 352: 854-865.
49. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. (1998) Lancet 352: 837-853.
50. Wallace TM, Matthews DR. (2002) Coefficient of failure: a methodology for examining longitudinal beta-cell function in Type 2 diabetes. Diabet Med 19: 465-469. (Pubitemid 34639156)
51. Robertson RP. (2009) Beta-cell deterioration during diabetes: what's in the gun? Trends Endocrinol Metab 20: 388-393.
52. van Raalte DH, Diamant M. (2011) Glucolipotoxicity and beta cells in type 2 diabetes mellitus: target for durable therapy? Diabetes Res Clin Pract 93 Suppl 1: S37-S46.
53. Furu K, Wettermark B, Andersen M, Martikainen JE, Almarsdottir AB, et al. (2010) The Nordic countries as a cohort for pharmacoepidemiological research. Basic Clin Pharmacol Toxicol 106: 86-94.
54. Willems SM, Mihaescu R, Sijbrands EJ, van Duijn CM, Janssens AC. (2011) A methodological perspective on genetic risk prediction studies in type 2 diabetes: recommendations for future research. Curr Diab Rep 11: 511-518.